|
⚲
|
| Keyboard |
| Symbiotic Capital Management Co LLC
✚
|
|
|---|---|
| CRD # | 325844 |
| SEC # | 801-128442 |
| CIK # | |
| AUM | 1,134.5 M (2026-03-31) |
| Employees | 9 (67% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 424-313-1550 |
| Address | 10100 Santa Monica Blvd Los Angeles, CA 90067 |
| Source | [IAPD] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 5 - FEES AND COMPENSATION Investors should consult the Funds Governing Documents for more details regarding the calculation of fees and expenses. Management Fee The Adviser will receive an annual management fee (the “Management Fee”) with respect to each Limited Partner equal to 1.75% per annum multiplied by the sum of (i) such Limited Partner’s capital contributions relating to all portfolio investments that have not been the subject of a disposition or write off, together with expenses related thereto, (ii) any outstanding and binding commitments by the Fund, in each case calculated as an average of the first day and the last day of such quarter and (iii) the non-cash proceeds of any portfolio investment if and to the extent the same do not constitute proceeds from a disposition. Any indebtedness incurred in lieu of a capital contribution will be treated as a capital contribution for purposes of calculating the Management Fee. For purposes of clauses (i) and (ii), capital contributions related to portfolio investments and binding commitments to make portfolio investments shall, in each case, be deemed to have been outstanding for a 90-day period prior to the closing of such investment. The Management Fee is subject to reduction as provided below in “Organizational Expenses” and “Fee Income.” The Management Fee is payable quarterly in arrears from drawdowns of the Limited Partners’ unfunded Commitments (or use of the subscription line) or other proceeds received by the Fund. Performance-Based Compensation As described in further detail in the Funds Governing Documents, the General Partner will receive performance-based compensation in the form of an incentive fee (“Carried Interest”) equal to 20%, with a threshold of 8%. Co-Investments The General Partner may, in its sole discretion, allocate co-investment opportunities to strategic and other investors, lenders, and/or one or more Limited Partners. Co-investment opportunities may be made available through limited partnerships or other entities formed to make such investments, with or without payment of a carried interest or management fee (a “Co-Investment Fund”). The General Partner will allocate available investment opportunities among the Fund, any Co-Investment Fund, and any third parties as it may in its sole discretion determine. The terms of co-investments may differ from those of the Fund, including with respect to the payment of carried interest and management fees. At its discretion, the General Partner may also structure any co-investment opportunity such that participants in such co-investment opportunity do not bear any broken deal expenses, resulting in the Fund bearing all such broken deal expenses. Organizational and Operating Expenses The Funds will bear all legal and other expenses incurred in the formation of the Funds and the offering of the Interests (other than any placement fees), up to an amount not to exceed amounts described in the LPA. Organizational expenses in excess of this amount, and any placement fees, will be borne by the Adviser through a 100% offset against the Management Fee (if paid by the Fund) or otherwise. The Adviser will pay all normal operating expenses incidental to the provision of the day-to-day administrative services to the Fund, including salaries for its employees and rent, utilities and other ordinary and recurring expenses of management. As further described in the Partnership Agreements, the Funds will pay all costs, expenses, and liabilities in connection with its operations and activities (“Fund Expenses”), including: fees and expenses related to consummated and unconsummated investments, including the evaluation, acquisition, holding and disposition thereof; interest on and fees and expenses related to or arising from indebtedness or hedging activities of the Funds; insurance premiums; taxes; fees and expenses of accountants, counsel, and consultants; legal, custodial, administration, auditing, accounting and regulatory and compliance expenses; costs of reporting to and meeting with the Partners and governmental authorities; costs and expenses of the Advisory Committee and the annual meeting; litigation expenses; and other extraordinary expenses. Side Letters The General Partner may enter into side letters or other agreements with individual Limited Partners that have the effect of establishing rights under, or altering or supplementing, the terms of the Partnership Agreement. Any rights established or any terms of the Partnership Agreement altered or supplemented in a side letter with a Limited Partner will govern with respect to such Limited Partner. In addition, the General Partner may permit certain Limited Partners, including those that are affiliated with the General Partner (including for these purposes any executive partner, officer, employee, service provider, advisor or team member of the Adviser or its affiliates and, in each case, their respective family members, estate planning vehicles and family offices), to invest in the Funds on a no fee or reduced fee and/or no Carried Interest or reduced Carried Interest basis. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 7 - TYPES OF CLIENTS The Adviser’s clients are the Funds. Currently, all Clients are Funds, structured as limited partnerships formed in Delaware and operate pursuant to one or more exemptions from registration under the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Limited Partners in the Funds are expected to include taxable and tax-exempt entities and may include institutions from non-US jurisdictions. The minimum capital commitment for a limited partner of the Funds is $10 million, although the General Partner may accept capital commitments of lesser amounts. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | SC Healthcare Credit Parallel Fund II A LP | [2026-03-31] | 100.0 M | 117.5 M |
| Filed 2025-11-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $7,500,000 · Revenue Decline to Disclose | ||||
| Other | SC Opportunities Holding LP | 2026-03-31 | 34.7 M | |
| Other | Symbiotic Capital Healthcare Credit Fund II LP | [2026-03-31] | 67.5 M | 115.7 M |
| Filed 2025-11-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $7,500,000 · Revenue Decline to Disclose | ||||
| Other | Symbiotic Capital Healthcare Credit Parallel Fund II LP | [2026-03-31] | 137.9 M | 155.0 M |
| Filed 2025-11-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $7,500,000 · Revenue Decline to Disclose | ||||
| Other | SC Life Science Credit Parallel Fund A LP | [2025-03-31] | 242.4 M | 247.4 M |
| Filed 2025-05-23 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | Symbiotic Capital EB Fund LP | [2025-03-31] | 15.1 M | |
| Filed 2025-03-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Symbiotic Capital EB Parallel Fund LP | [2025-03-31] | 8.8 M | |
| Filed 2025-03-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Symbiotic Capital Life Science Credit Fund LP | [2023-06-01] | 160.2 M | 172.5 M |
| Filed 2025-05-23 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $1,200,000 · Net Assets Decline to Disclose | ||||
| Other | Symbiotic Capital Life Science Credit Parallel Fund LP | [2023-06-01] | 176.4 M | 267.7 M |
| Filed 2025-05-23 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $1,200,000 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 9 | 1,134.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 1,134.5 |
| By Discretionary | ||
| Discretionary | 8 | 1,099.8 |
| Non-Discretionary | 1 | 34.7 |
| Total | 9 | 1,134.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 370.8 | |
| United States Persons | 763.7 | |
| Total | 9 | 1,134.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Arie Belldegrun | Director | 50 | 6 | |
| Joshua Kazam | Director | 60 | 3 | |
| Daniel Kim | Director | 47 | 3 | |
| Joshua Bradley | Director | 32 | 3 | |
| Benjamin Belldegrun | Director | 7 | 3 | |
| Franz Humer | Director | 6 | 2 | |
| Russell Goldsmith | Director | 8 | 1 | |
| Himani Bhalla | Director | 8 | 1 | |
| Symbiotic Capital Life Science Credit Fund GP LP | Promoter | 5 | 1 | |
| Symbiotic Capital Healthcare Credit Fund II GP LP | Promoter | 3 | 1 | |
| View All | ||||
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Comparable Firms | State | AUM |
|---|---|---|
|
Astatine Asset Management LLC
✚
|
CT | 1,150.1 M |
|
Viking Fund Management LLC
✚
|
ND | 1,149.5 M |
|
1WS Capital Advisors LLC
✚
|
NY | 1,142.6 M |
|
Yosemite Management LLC
✚
|
CA | 1,135.7 M |
|
HM International LLC
✚
|
TX | 1,134.4 M |
|
iCapital Fund Advisors LLC
✚
|
NY | 1,132.6 M |
|
Amundi US Investment Advisors LLC
✚
|
MA | 1,132.5 M |
|
Moonrise Capital LP
✚
|
FL | 1,128.2 M |
|
WITT Lake Asset Management LLC
✚
|
CT | 1,120.4 M |
|
New Century Partners
✚
|
1,118.9 M |